Current treatment status-Undergoing active treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment Posts on Medivizor

Evaluating combination CAR-T cell therapy for recurrent or treatment-resistant multiple myeloma

Posted by on Oct 6, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of combining two T-cell therapies for multiple myeloma (MM) that has come back or stopped responding to treatment. This study concluded that this treatment showed promising effectiveness for these patients. Some background Treatment for patients with MM that has come back (relapsed)...

Read More

Does remission status influence outcomes of SCT for patients with Hodgkin’s lymphoma?

Posted by on Sep 21, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of allogeneic stem cell transplantation (SCT) in patients with classical Hodgkin’s lymphoma (CHL) that was refractory (resistant to treatment) or had relapsed. The study found that patients in complete remission (no signs of cancer) when they received the transplant had better outcomes. Some...

Read More

Lymphoma transformation risk in patients with advanced follicular lymphoma

Posted by on Sep 20, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the frequency of lymphoma transformation in patients with advanced-stage follicular lymphoma (FL) after treatment with BR (bendamustine, rituximab). This study concluded these patients might be at risk for lymphoma transformation after initial treatment. Some background FL is the second most common type of...

Read More

Evaluating pembrolizumab for patients with reoccurring classical Hodgkin’s lymphoma

Posted by on Sep 2, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) for patients with classical Hodgkin’s lymphoma (cHL) that came back after initial treatment. This study concluded that pembrolizumab was effective for these patients, with manageable side effects. Some background First-line chemotherapy is highly...

Read More

Evaluating GVDex chemotherapy for patients with recurrent or persistent Hodgkin’s lymphoma

Posted by on Aug 19, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined if GVDex is as effective and safe as GVDoxil for treating Hodgkin's lymphoma (HL) that has come back or stopped responding to treatment. The authors found that GVDex was as effective as GVDoxil, with fewer side effects. Some background For most patients with HL, primary therapy is highly effective....

Read More

Evaluating nivolumab plus brentuximab vedotin for patients with relapsed or unresponsive primary mediastinal large B-cell lymphoma

Posted by on Aug 17, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated nivolumab (Opdivo) plus brentuximab vedotin (Adcetris) in patients with relapsed or unresponsive primary mediastinal B-cell lymphoma (PMBCL). This study concluded that this combination is promising and was well-tolerated. Some background PMBCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL)....

Read More

Comparing outcomes in patients with chronic lymphocytic leukemia with detectable and undetectable minimal residual disease

Posted by on Jul 31, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to compare the outcomes for patients with chronic lymphocytic leukemia who achieved detectable and undetectable minimal residual disease (MRD).   This study concluded that patients with undetectable MRD had better outcomes than those with detectable MRD.  Some background Minimal...

Read More

EndoPredict – can this prognostic test predict treatment success in breast cancer?

Posted by on May 30, 2019 in Breast cancer | 0 comments

In a nutshell This study investigated if a prognostic tool called EndoPredict can predict the success of treatment in hormone receptor-positive breast cancer (BC). They found that high scores using EndoPredict predicted treatment benefit in patients with BC.  Some background Breast cancer (BC) is one of the most common cancers. BC treatment...

Read More

Evaluating isatuximab plus pomalidomide and dexamethasone for non-responsive multiple myeloma

Posted by on May 11, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated  isatuximab, pomalidomide (Imnovid) and dexamethasone (Decadron) for recurrent or non-responsive multiple myeloma (MM). This study concluded that this treatment combination was safe and effective for these patients. Some background There are several treatment options for patients with MM. Most initial...

Read More

Evaluating scoring systems used to predict outcomes for patients with advanced HL

Posted by on Apr 24, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the effectiveness of the International Prognostic Scoring System (IPSS) measuring 7 factors (IPSS7) versus the IPSS measuring 3 factors (IPSS3) in predicting outcomes for patients with Hodgkin's lymphoma (HL). This study concluded that there was no significant difference between these scoring systems. Some...

Read More